致编辑的信：“对需要全身治疗的转移性疾病患者的甲状腺癌进行Foundation One™基因组检测” - Suppr

Suppr

超能文献

Letter to the Editor: "Foundation One™ Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy".

作者信息

Pitoia Fabián, Smulever Anabella, Jerkovich Fernando

机构信息

Division of Endocrinology, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina.

出版信息

J Clin Endocrinol Metab. 2020 Sep 1;105(9). doi: 10.1210/clinem/dgaa421.

DOI:10.1210/clinem/dgaa421

PMID:32609345

Abstract

摘要

相似文献

Letter to the Editor: "Foundation One™ Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy".致编辑的信：“对需要全身治疗的转移性疾病患者的甲状腺癌进行Foundation One™基因组检测”

J Clin Endocrinol Metab. 2020 Sep 1;105(9). doi: 10.1210/clinem/dgaa421.

Genomic Hallmarks of Thyroid Neoplasia.甲状腺肿瘤的基因组特征。

Annu Rev Pathol. 2018 Jan 24;13:141-162. doi: 10.1146/annurev-pathol-121808-102139. Epub 2017 Oct 30.

Response to Letter to the Editor on COI for American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules.对致编辑的信的回复，该信涉及美国甲状腺协会关于甲状腺结节分子谱分析手术应用声明中的利益冲突。

Thyroid. 2015 Nov;25(11):1266. doi: 10.1089/thy.2015.0446. Epub 2015 Oct 20.

Using Ion Torrent sequencing to study genetic mutation profiles of fatal thyroid cancers.应用 Ion Torrent 测序技术研究致命性甲状腺癌的基因突变谱。

J Formos Med Assoc. 2018 Jun;117(6):488-496. doi: 10.1016/j.jfma.2017.05.007. Epub 2017 Jul 27.

Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist?甲状腺癌基因组特征对甲状腺病理学的影响：滤泡状变异型甲状腺乳头状癌是否存在？

Thyroid. 2015 Jan;25(1):1-2. doi: 10.1089/thy.2014.0540.

Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.综合基因组分析有助于区分转移性复发与第二原发性癌症。

Oncologist. 2017 Feb;22(2):152-157. doi: 10.1634/theoncologist.2015-0511. Epub 2017 Feb 13.

Other primary systemic cancers in patients with melanoma: Analysis of balanced acral and nonacral melanomas.黑色素瘤患者的其他原发性系统性癌症：平衡肢端和非肢端黑色素瘤的分析。

J Am Acad Dermatol. 2016 Feb;74(2):333-40. doi: 10.1016/j.jaad.2015.09.047. Epub 2015 Nov 12.

Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers.原发性甲状腺癌放疗作为第二原发性癌症的一个危险因素。

Cancer Lett. 2006 Jul 8;238(1):42-52. doi: 10.1016/j.canlet.2005.06.015. Epub 2005 Jul 21.

Reply to the Letter to the Editor 'Germline-somatic fluidity in guiding patient care. Reply to the Letter to the Editor "Choice of control tissue impacts designation of germline variants in a cohort of papillary thyroid carcinoma patients" by J. C. Rubinstein et al.' by E. Hahn & G. S. Charames.对编辑来信《生殖系-体细胞的流动性在指导患者护理中的作用。对J. C. 鲁宾斯坦等人的编辑来信〈对照组织的选择对一组甲状腺乳头状癌患者生殖系变异的认定的影响〉的回复》的回复，作者为E. 哈恩和G. S. 查拉姆斯

Ann Oncol. 2020 Aug;31(8):1090-1091. doi: 10.1016/j.annonc.2020.04.482. Epub 2020 May 16.

Gene-expression profiling in differentiated thyroid cancer--a viable strategy for the practice of genomic medicine?分化型甲状腺癌中的基因表达谱分析——基因组医学实践的可行策略？

Future Oncol. 2005 Aug;1(4):497-510. doi: 10.2217/14796694.1.4.497.

引用本文的文献

Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience.达布拉非尼联合曲美替尼治疗间变性甲状腺癌：阿根廷经验。

Endocrine. 2023 Apr;80(1):134-141. doi: 10.1007/s12020-022-03295-2. Epub 2023 Jan 9.

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an gene fusion.携带基因融合的甲状腺乳头状癌患者对拉罗替尼治疗的完全缓解。（注：原文中“an gene fusion”表述有误，推测应为“a gene fusion”之类正确表述，但按要求不做修改直接翻译）

Clin Case Rep. 2021 Feb 20;9(4):1905-1912. doi: 10.1002/ccr3.3900. eCollection 2021 Apr.

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.达拉非尼联合曲美替尼治疗间变性甲状腺癌的显著临床疗效及 COVID-19 大流行期间面临的挑战。

Arch Endocrinol Metab. 2021 Nov 1;65(2):242-247. doi: 10.20945/2359-3997000000325. Epub 2021 Feb 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验